X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U. countries.
Lead Product(s): Naproxen Sodium,Sumatriptan
Therapeutic Area: Neurology Product Name: Suvexx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 15, 2023
Details:
Through the acquisition, Tonix gets two FDA approved products including, Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), indicated for the treatment of acute migraine in adults.
Lead Product(s): Sumatriptan
Therapeutic Area: Neurology Product Name: Zembrace SymTouch
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: $25.0 million Upfront Cash: $22.0 million
Deal Type: Acquisition July 03, 2023
Details:
The acquisition of two currently-marketed products Zembrace SymTouch (sumatriptan succinate injection) and Tosymra (sumatriptan nasal spray), complement Tonix’s current intranasal clinical development program of TNX-1900 for migraine prevention.
Lead Product(s): Sumatriptan
Therapeutic Area: Neurology Product Name: Zembrace SymTouch
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: $25.0 million Upfront Cash: $22.0 million
Deal Type: Acquisition June 26, 2023
Details:
Cipla’s Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline’s Imitrex® Nasal Spray.
Lead Product(s): Sumatriptan
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
Details:
Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estonia.
Lead Product(s): Naproxen Sodium,Sumatriptan
Therapeutic Area: Neurology Product Name: Suvexx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Undisclosed Upfront Cash: $2.0 million
Deal Type: Partnership December 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
